Bausch + Lomb SeeLyra CE Mark Approval
Analysis based on 6 articles · First reported Sep 11, 2026 · Last updated Sep 11, 2026
The CE Mark approval strengthens Bausch Health — Bausch & Lomb's competitive position in the European ophthalmic surgical device market and could support incremental revenue growth from premium cataract and LASIK procedures. The impact is likely modest and company-specific, with limited broader market implications.
Bausch Health — Bausch & Lomb Corporation announced that the European Union granted CE Mark approval for SeeLyra, its next-generation femtosecond laser platform. SeeLyra is designed to provide surgeons with enhanced precision and control in laser-assisted preparation for premium cataract, LASIK flap and corneal therapeutic surgeries. The compact system integrates real-time swept source OCT imaging, enabling accurate depth visualization and precise positioning of laser cuts, and its mobility and versatile configurations are tailored for modern, space-constrained operating rooms. Building on more than 15 years of experience in femtocataract laser technology, SeeLyra retains key features from Bausch Health — Bausch & Lomb's earlier VICTUS platform while introducing new capabilities. SeeLyra will be available in Europe on a limited basis in the coming months, with broader availability expected in 2027. Bausch Health — Bausch & Lomb is also seeking regulatory approvals for SeeLyra in markets around the world, including the United States, with indications and approvals varying by country. The approval expands the company's surgical technology offerings in Europe and supports its premium cataract and refractive surgery franchise.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard